Form 4: Monopar Therapeutics CEO Chandler Robinson Reports Significant RSU Vesting and Share Transactions

Monopar Therapeutics CEO and Director Chandler Robinson reported the vesting of 13,344 restricted stock units and the subsequent disposition of 5,865 shares for tax withholding, alongside an indirect beneficial ownership of 822,255 shares.

Summary

• Chandler Robinson, Chief Executive Officer and Director of Monopar Therapeutics, acquired 13,344 shares of common stock on June 30, 2025, through the vesting and settlement of restricted stock units (RSUs).
• Concurrently, 5,865 shares were disposed of at a price of $35.78 per share to cover applicable withholding taxes due upon the RSU vesting.
• Following these transactions, Robinson directly beneficially owns 73,472 shares of common stock.
• Robinson also indirectly beneficially owns 822,255 shares of common stock through Tactic Pharma LLC, though he disclaims beneficial ownership except to the extent of his pecuniary interest.
• The 13,344 shares acquired on June 30, 2025, resulted from scheduled vesting of multiple RSU grants: 1,994 shares from a February 2, 2022 grant, 2,113 shares from a February 1, 2023 grant, and 9,237 shares from a March 4, 2025 grant.
• As of June 30, 2025, Robinson directly holds 81,325 derivative securities in the form of restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there's a disposition of shares, it's for tax purposes related to RSU vesting, which represents a planned compensation event and an increase in direct ownership. The CEO maintains a significant direct and indirect stake, aligning interests with shareholders.

Positives

• The vesting of 13,344 restricted stock units indicates continued long-term incentive compensation for the CEO, aligning management interests with shareholder value.
• The significant indirect beneficial ownership of 822,255 shares through Tactic Pharma LLC demonstrates a substantial stake in the company.

Negatives

• Disposition of 5,865 shares at $35.78 to cover tax liabilities reduces the direct shareholding of the CEO.

Risks

• NA

Future Outlook

The document details future vesting schedules for restricted stock units granted to Chandler Robinson, with full vesting dates extending to December 31, 2025, December 31, 2026, and December 31, 2028, indicating a long-term incentive structure for the CEO.

Management Comments

• NA

Industry Context

NA

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• Chandler Robinson's indirect beneficial ownership of 822,255 shares through Tactic Pharma LLC, where he is a manager, represents a related party interest. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: The vesting of RSUs and subsequent increase in direct ownership by the CEO can be seen as a positive signal of management's continued commitment and alignment with shareholder interests. The tax-related disposition is a routine event.
• Employees: The RSU vesting structure indicates a standard equity compensation program for executives, which may reflect broader compensation practices within the company.

Next Steps

• Continued periodic vesting of restricted stock units for Chandler Robinson on a quarterly basis until December 31, 2025, for the 2022 grant.
• Continued periodic vesting of restricted stock units for Chandler Robinson on a quarterly basis until December 31, 2026, for the 2023 grant.
• Continued periodic vesting of restricted stock units for Chandler Robinson on a quarterly basis until December 31, 2028, for the 2025 grant.

Key Dates

Recommendation

Keywords

Monopar Therapeutics, MNPR, Chandler Robinson, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Ownership, CEO, Director, Tax Withholding, Beneficial Ownership, Equity Compensation